Mémoire numérisé par la Direction des bibliothèques de l'Université de Montréal. / Une épreuve ELISA indirecte a été développée pour la détection d'anticorps antileptospires dans des sérums d'origine canine. Une préparation antigénique spécifique de genre, stable à la chaleur et produite à partir de Leptospira interrogans sérovar Pomona a été utilisée dans cette technique immuno-enzymatique. D'autre part, une détermination de la prévalence des séroréacteurs envers différents sérovars de leptospires a été effectuée chez l'espèce canine au Québec, à raide du test ELISA et du test d'agglutination microscopique (MAT). La préparation antigénique, élaborée à partir du sérovar Pomona, a réagi avec les sérums de lapin contre les sérovars Bratislava, Pomona, Autumnalis, Grippotyphosa et Icterohaemorrhagiae. Cette technique ELISA a démontré une spécificité relative de 95.6% avec 158 sérums d'origine canine, lesquels étaient négatifs à une dilution de 1:100, par le MAT, envers les sérovars Pomona, Bratislava, Icterohaemorrhagiae, Autumnalis, Grippotyphosa et Hardjo. La sensibilité relative de l'épreuve a été de 100% avec 21 sérums d'origine canine, lesquels démontraient des titres supérieurs ou égaux à 1:100 envers un ou plusieurs sérovars. Parmi les chiens qui présentaient des titres d'anticorps anti-leptospires, le titre prédominant était dirigé contre le sérovar Pomona dans 66.7% des cas (14/21). Des titres prédominants contre le sérovar Bratislava ont été trouvés chez deux chiens, alors qu'un titre prédominant contre Grippotyphosa a été trouvé chez un seul animal. Quatre chiens ont uniquement présenté une réaction 1:100 contre le sérovar Icterohaemorrhagiae. Cette épreuve ELISA s'est avérée facile à standardiser et techniquement plus avantageuse que le MAT, par le fait qu'elle utilise une préparation antigénique qui peut être préparée de routine et en grandes quantités. En conclusion, il apparaît que cette épreuve est sensible et elle serait utilisable comme épreuve de tamisage pour la recherche d'anticorps anti-leptospires chez l'espèce canine, avec une confirmation subséquente des résultats positifs par le MAT.

No description available.

Die vorliegende Arbeit beschreibt die Herstellung und Charakterisierung der ersten Antikörper gegen Triacetontriperoxid (TATP), einem hoch empfindlichen und unkonventionellen (nicht-kommerziellen) Initialsprengstoff. Entscheidend dafür war die Synthese eines TATP-imitierenden Haptens, welches die typische nonagonale Struktur des TATP mit seinen drei Peroxid- und sechs Methylgruppen nahezu perfekt nachbildet, aber den Vorzug einer zusätzlichen Carboxygruppe zur kovalenten Kopplung an Proteine aufweist. Dadurch konnte das TATP-Hapten an Rinderserumalbumin (BSA) gebunden werden, um ein immunogenes Konjugat zu erzeugen, welches die erfolgreiche Immunisierung zweier Säugetierarten, Maus und Kaninchen, ermöglichte. Der Verlauf der In vivo-Immunisierungen wurde durch die Analyse der Tierseren in regelmäßigen Abständen mittels enzymgekoppeltem Immunoassay (ELISA) verfolgt. Die polyklonalen Antikörper beider Spezies waren ungewöhnlich selektiv gegenüber TATP. Jedoch unterschied sich die Affinität der Antikörper der zwei Spezies um das 5000-fache, wobei die Kaninchenseren den Mausseren überlegen waren. Entsprechend war auch die mit Kaninchenserum erreichbare TATP-Nachweisgrenze von 0.01 µg/L deutlich besser im Vergleich zu 50 µg/L, die mit Mausserum erzielt wurden. Der Messbereich des TATP-ELISA mit Kaninchenserum deckte zudem mehr als vier Zehnerpotenzen ab, wie mittels Präzisionsprofil bestimmt wurde. Die erhaltenen TATP-Antikörper aus Kaninchen stehen damit Anwendungen in Nachweissystemen für die sehr empfindliche Detektion von TATP zur Verfügung, die u. a. in sicherheitsrelevanten Bereichen zum Einsatz kommen könnten. Als erste Anwendung wurde ein TATP-ELISA realisiert, der im Rahmen dieser Arbeit ausführlich optimiert wurde. Außerdem wurden erste Schritte zur Entwicklung eines TATP-Schnelltests (LFA) unternommen. Weitere Biosensoren auf Grundlage der neu entwickelten TATP-Antikörper sind denkbar. / The present work decribes the production and characterization of the first antibodies against triacetone triperoxide (TATP), a highly sensitive and improvised (non-commercial) primary explosive. Crucial to this work was the synthesis of a TATP-related hapten that mimics almost perfectly the typical nonagonal structure of TATP with its three peroxide and six methyl groups. Advantageously, it has an additional carboxylic acid group, which provides a conjugation site for covalent attachment to proteins. Thus, the TATP hapten could be linked to bovine serum albumin (BSA) to produce an immunogenic conjugate, allowing the successful immunization of two different mammalian species, mouse and rabbit. The in vivo immunization progress was followed by periodically analyzing the animals’ sera using enzyme-linked immunosorbent assay (ELISA). The polyclonal antibodies of both species were remarkably selective to TATP. The affinity of these TATP-antibodies was, however, different between the two species, with the rabbit sera showing an affinity about 5000-fold superior than the murine one. Consequently, the TATP detection limit of 0.01 µg/L was considerably better using the sera from rabbit in contrast to 50 µg/L when mouse serum was used. The working range of the TATP-ELISA with rabbit sera covers more than four decades, calculated from a precision profile. The obtained TATP antibodies from rabbit are now available for applications in highly sensitive detection systems for TATP, which could be employed, among others, in security-relevant areas. The first application was the realization of a TATP-ELISA, which was extensively optimized within the course of this work. Furthermore, the first steps towards the development of a lateral flow assay (LFA) targeting TATP were taken, making conceivable further biosensor platforms based on the newly developed TATP antibodies.

No description available.

No description available.

No description available.

Le présent travail a porté sur l’évaluation des propriétés anti-inflammatoires et anticancéreuses de Agelanthus dodoneifolius (Loranthaceae), communément appelée «gui africain». Cette plante hémiparasite est utilisée en médecine traditionnelle africaine pour le traitement de pathologies chroniques telles que l’asthme, l’hypertension, des gastroentérites et le cancer. Actuellement, les maladies chroniques représentent un problème mondial de santé publique. En effet, elles constituent la première cause de mortalité dans le monde surtout dans les pays à revenu faible ou intermédiaire. <p><p>Cette étude a été réalisée dans le but d’apporter une validation scientifique quant à certaines utilisations traditionnelles de Agelanthus dodoneifolius. <p>Pour évaluer l’effet anti-inflammatoire de Agelanthus dodoneifolius, nous avons testé les différentes fractions de la plante sur la production des espèces réactives de l’oxygène, la libération et l’activité spécifique de la myéloperoxydase (MPO), enzyme libérée par le neutrophile au cours de la phagocytose pour détruire les microorganismes. L’identification et la quantification des composés a été faite grâce à une combinaison des méthodes chromatographiques, spectrophotométriques et spectrométriques. L’activité anticancéreuse de Agelanthus dodoneifolius a consisté, d’abord, à déterminer l’effet d’inhibition de croissance de diverses fractions de la plante, de la quercétine ainsi que de ses dérivés sur des lignées cellulaires cancéreuses. Nous avons ensuite déterminé les effets de la quercétine sur l’activité de plus de 300 kinases. <p><p>Les résultats obtenus montrent qu’Agelanthus dodoneifolius est capable de moduler les activités biologiques des neutrophiles. En effet, le décocté aqueux et les fractions organiques de la plante inhibent de manière dose-dépendante la production des espèces réactives de l’oxygène, la dégranulation du neutrophile et l’activité spécifique de la myéloperoxydase. Nous avons pu identifier et quantifier dix composés polyphénoliques dont quatre acides phénoliques :l’acide gallique, l’acide coumarique, l’acide chlorogénique et l’acide ellagique et six flavonoïdes :la quercétine, le kaempférol, la catéchine, l’isoquercitrine ou quercétine 3-O-glucoside, la rutine et la miquelianine ou quercétine-3-O-glucuronide. <p>Concernant l’activité anticancéreuse, les résultats montrent que seules les fractions à l’éther diéthylique et à l’acétate d’éthyle ont une activité antiproliférative. La quercétine a des effets inhibiteurs de croissance, cytostatiques et présente un large spectre d’activité sur plusieurs kinases surexprimées dans certains cancers. <p><p>En conclusion, l’ensemble de ces résultats constitue des bases scientifiques qui pourraient justifier certaines utilisations traditionnelles de Agelanthus dodoneifolius. <p>À notre connaissance, cette étude est la première à évaluer d’une part l’effet, in vitro, des différentes fractions de Agelanthus dodoneifolius sur des neutrophiles stimulés et sur la MPO et d’autre part l’effet inhibiteur de croissance de lignées cellulaires cancéreuses par certaines fractions de la plante. En outre, cette étude a permis pour la première fois d’identifier et de quantifier des composés polyphénoliques dans Agelanthus dodoneifolius. Les nombreuses propriétés de ces composés, notamment celles anti-inflammatoires et anticancéreuses, peuvent expliquer en partie les résultats reportés dans ce travail.<p><p>This work focused on evaluating anti-inflammatory and anticancer activities of Agelanthus dodoneifolius (Loranthaceae), commonly called "African mistletoe". This plant is used in African traditional medicine for the treatment of chronic conditions such as asthma, hypertension, gastroenteritis and cancer. Currently, chronic diseases are a global public health problem. Indeed, they are the leading cause of death worldwide, especially in countries with low and middle income.<p>The study was conducted to provide scientific validation for some traditional uses of Agelanthus dodoneifolius.<p><p>To characterize the anti-inflammatory activity of Agelanthus dodoneifolius, we tested the different fractions of the plant on reactive oxygen species production, release and the specific activity of myeloperoxidase, an enzyme released by neutrophils during phagocytosis to destroy microorganisms. The identification and quantification of compounds were made through a combination of chromatographic, spectrophotometric and spectrometric techniques. The anticancer activity of Agelanthus dodoneifolius consisted, first, to determine, the antiproliferative effect of fractions of the plant, quercetin and its derivatives on cancer cell lines. Then, we determined the effects of quercetin on the activity of more than 300 kinases.<p><p>The results show that Agelanthus dodoneifolius is capable of modulating the biological activities of neutrophils. In fact, the decoction aqueous and organic fractions of the plant inhibited in a dose-dependent manner the production of reactive oxygen species, degranulation of neutrophils and specific activity of myeloperoxidase. <p>We were able to identify and quantify ten polyphenolic compounds including four phenolic acids: gallic acid, coumaric acid, chlorogenic acid and ellagic acid and six flavonoids: quercetin, kaempferol, catechin, isoquercitrin or quercetin 3-O-glucoside, rutin and miquelianin or quercetin-3-O-glucuronide.<p>Regarding the anticancer activity, the results show that only fractions with diethyl ether and ethyl acetate have antiproliferative activity. Quercetin has antiproliferative and cytostatic effects and presents a broad spectrum of activity on several kinases overexpressed in certain cancers.<p><p>In conclusion, all these findings are scientific basis that could justify some traditional uses of Agelanthus dodoneifolius. To our knowledge, this is the first study to evaluate the effect firstly, by in vitro tests, of the different fractions of Agelanthus dodoneifolius on stimulated neutrophils and the MPO and secondly the growth inhibitory effect of cancer cell lines by certain fractions. Also, this study is the first to identify and quantify the phenolic compounds in Agelanthus dodoneifolius. The many properties of these compounds, including anti-inflammatory and anticancer, may partly explain the results reported in the present work. / Doctorat en Sciences biomédicales et pharmaceutiques / info:eu-repo/semantics/nonPublished

Abstract Endometrial carcinoma is the most common gynegologic malignancy in developed countries. Due to early symptoms, including abnormal uterine bleeding, endometrial cancer is often diagnosed at an early stage and in that case usually has a good prognosis and high cure rates. However, the nature of the disease is heterogeneous. During the last decades, the improvement in survival rates among endometrial cancer patients has not been significant, suggesting that the traditional clinicopathological factors may be inadequate to identify patients with high-risk disease. Furthermore, aggressive adjuvant treatments can be costly and very toxic. Therefore, better prognostic markers associated with biological aggressiveness of endometrial carcinoma are needed to identify the patients with high-risk disease, and to be able to select the treatment more individually. Gelatinases (MMP-2 and MMP-9) and their tissue inhibitors (TIMP-1 and TIMP-2) have been found to play a role in tumor progression. In the present work, the expression and prognostic value of MMP-2, MMP-9, TIMP-1 and TIMP-2 were assessed in endometrial carcinoma. The patient material consisted of a total of 266 women diagnosed with primary endometrial carcinoma. The tissue expression of immunoreactive proteins was examined in paraffin-embedded tumor sections by immunohistochemical staining using specific antibodies, and the pretreatment serum levels of the proteins were quantitatively measured by ELISA. Tissue MMP-2 expression associated with a worsened prognosis, whereas tissue TIMP-2 overexpression was an indicator of a favorable outcome. Furthermore, we observed a combination of strong MMP-2 and weak TIMP-2 tissue expression to identify a group of women at high risk of adverse outcome in endometrial carcinoma. Patients with negative MMP-2 immunostaining had the best prognosis, regardless of TIMP-2 staining result. In serum measurements, high preoperative TIMP-1 concentration was a prognostic indicator of unfavorable outcome. These results indicate that tissue MMP-2 and TIMP-2 as well as circulating TIMP-1 may be prognostic markers in endometrial carcinoma. Of these, tissue MMP-2 seems to be the most potent prognostic marker. Studies with larger patient materials are needed to further explore the value of these enzymes in clinical practice in endometrial cancer. / Tiivistelmä Kohdunrungon syöpä on yleisin gynekologinen maligniteetti kehittyneissä maissa. Varhaisten oireiden, kuten poikkeavan verisen vuodon, vuoksi kohdunrungon syöpä havaitaan usein varhaisessa vaiheessa, jolloin sen ennuste on hyvä. Taudin käyttäytyminen voi kuitenkin olla moninaista. Viime vuosikymmenten aikana kohdunrungon syöpään sairastuneiden ennuste ei ole merkittävästi parantunut. Vaikuttaisi siltä, että perinteiset ennustetekijät eivät ole riittävän tarkkoja ennustamaan syövän taudinkulkua. Lisäksi liitännäishoidot voivat olla kalliita, ja niihin voi liittyä vakavia haittavaikutuksia. Uusien biologisten ennustetekijöiden löytäminen olisi tärkeää, jotta aggressiivista syöpätyyppiä sairastavat potilaat pystyttäisiin tunnistamaan entistä paremmin, ja hoito kyettäisiin räätälöimään yksilöllisemmin taudinkuvaa vastaavasti. Gelatinaasien (MMP-2 ja MMP-9) sekä niiden kudosinhibiittoreiden (TIMP-1 ja TIMP-2) on havaittu osallistuvan syövän etenemiseen. Tässä tutkimuksessa tarkasteltiin MMP-2:n ja MMP-9:n sekä niiden kudosinhibiittoreiden TIMP-1:n ja TIMP-2:n ilmentymistä ja ennusteellista merkitystä kohdunrungon syövässä. Aineisto käsitti yhteensä 266 primaariseen kohdunrungon syöpään sairastunutta naista. Määritysmenetelminä käytettiin sekä immunohistokemiallista värjäystä parafiiniin valettujen kudosnäytteiden osalta että ELISA-määrityksiä ennen hoitoa otettujen seeruminäytteiden osalta. Syöpäkudoksen runsas MMP-2 -proteiinin ilmentyminen liittyi epäsuotuisaan ennusteeseen, kun taas kasvainkudoksen voimakas TIMP-2 -proteiinin ilmentyminen oli hyvän ennusteen merkki. Lisäksi kasvainkudoksen voimakkaan MMP-2- ja heikon TIMP-2 -proteiinien ilmentymisen yhdistelmän havaittiin liittyvän suurempaan syövästä johtuvaan kuolleisuuteen. MMP-2 -negatiivisten potilaiden eloonjäämisennuste oli paras, TIMP-2 -värjäystuloksesta riippumatta. Seerumin korkea TIMP-1 -pitoisuus oli merkittävä huonontuneen ennusteen merkki. Tutkimuksen tulokset viittaavat siihen, että kasvainkudoksessa esiintyvät MMP-2- ja TIMP-2 -proteiinit samoin kuin seerumin TIMP-1 -pitoisuus voivat ennustaa kohdunrungon syövän kliinistä käyttäytymistä. Kasvainkudoksessa esiintyvä MMP-2 -proteiini vaikuttaisi olevan merkittävin ennusteellinen tekijä, mutta tulosten varmistamiseksi tarvitaan lisää tutkimuksia suuremmilla potilasaineistoilla.

The expanding aquaculture industry continues to encounter major challenges in the form of highly contagious aquatic viruses. Control and eradication measures targeting the most lethal and economically damaging virus-induced diseases, some of which are notifiable, currently involve ‘stamping out’ policies and surveillance strategies. These approaches to disease control are performed through mass-culling followed by restriction in the movement of fish and fish products, resulting in considerable impacts on trade. Although effective, these expensive, ethically complex measures threaten the sustainability and reputation of the aquatic food sector, and could possibly be reduced by emulating innovative vaccination strategies that have proved pivotal in maintaining the success of the terrestrial livestock industry. DIVA ‘differentiating infected from vaccinated animal’ strategies provide a basis to vaccinate and contain disease outbreaks without compromising ‘disease-free’ status, as antibodies induced specifically to infection can be distinguished from those induced in vaccinated animals. Various approaches were carried out in this study to assess the feasibility of marker/DIVA vaccination for two of the most important disease threats to the global Atlantic salmon and common carp/koi industries, i.e. infectious salmon anaemia (ISA) and koi herpesvirus disease (KHVD), respectively. Antibody responses of Atlantic salmon (Salmo salar L.), following immunisation with an ISA vaccine, administered with foreign immunogenic marker antigens (tetanus toxoid (TT), fluorescein isothiocyanate (FITC) and keyhole limpet hemocyanin (KLH)) were assessed by antigen-specific enzyme linked immunosorbent assay (ELISA). Although antibodies were induced to some markers, these were unreliable and may have been affected by temperature and smoltification. Detectable antibodies to ISAV antigen were also largely inconsistent despite low serum dilutions of 1/20 being employed for serological analysis. The poor antibody responses of salmon to the inactivated ISA vaccine suggested that DIVA vaccination is not feasible for ISA. A similar approach for KHV, utilising green fluorescent protein (GFP) as the marker, similarly failed to induce sufficiently detectable antibody responses in vaccinated carp (Cyprinus carpio L.). However, as high anti-KHV antibody titres were obtained with an inactivated KHV vaccine (≥1/3200), alternative approaches were carried out to assess the feasibility of DIVA vaccination for carp. Investigations of early KHV pathogenesis in vivo and antigen expression kinetics in vitro (0-10 days post infection (dpi)) provided valuable data for the diagnostics necessary for DIVA surveillance strategies. Following viral infection, molecular methods were shown to be the most effective approach for early detection of KHV infected fish prior to sero-conversion, during which time antibodies are not detectable. An experimental immersion challenge with KHV, however, revealed complications in molecular detection during early infection. The KHV DNA was detected in external biopsies of skin and gills, but also internally in gut and peripheral blood leukocytes ≤ 6 hours post infection (hpi), suggesting rapid virus uptake by the host. The gills and gut appeared to be possible portals of entry, supported by detection of DNA in cells by in situ hybridisation (ISH). However, many false negative results using organ biopsies occurred during the first 4 dpi. The gills were the most reliable lethal biopsy for KHV detection by various polymerase chain reaction (PCR) assays, with a PCR targeting a glycoprotein-gene (ORF56) and a real-time PCR assay being the most sensitive of the 7 methods investigated. Importantly, non-lethal mucus samples reduced the number of false negative results obtained by all KHV PCR assays during the earliest infection stages with large levels of viral DNA being detected in mucus (up to 80,000 KHV DNA genomic equivalents 200 μL-1). KHV DNA was consistently detected in the mucus as a consequence of virus being shed from the skin. Determining the expression kinetics of different viral structural proteins can be useful for DIVA serological tests. Analysis of KHV antigen expression in tissues by immunohistochemistry and indirect fluorescent antibody test was inconclusive, therefore 2 novel semi-quantitative immunofluorescence techniques were developed for determining KHV antigen expression kinetics in susceptible cell lines. During the course of KHV infection in vitro, a greater abundance of capsid antigen was produced in infected cells compared to a glycoprotein antigen (ORF56), as determined by detection with antigen-specific monoclonal antibodies (MAbs). The capsid antigen was characterised as a ~100 kDa protein by SDS-PAGE and identified as a product of KHV ORF84 by matrix-assisted laser desorption ionisation time-of-flight mass spectrometry (MALDI-TOF/TOF MS). This antigen was subsequently detected in the serum of >25% of KHV infected/exposed carp (6/17), as well as in carp vaccinated with a live attenuated vaccine (3/4), but not with an inactivated vaccine (0/7), by Western blot making it a potential DIVA target for an inactivated vaccine. Attempts were made to improve the sensitivity of KHV serological testing by taking advantage of recombinant proteins specific for KHV (CyHV-3), rORF62 and rORF68 and eliminating any interference by cross-reacting antibodies to carp pox (CyHV-1). These proteins successfully reacted with anti-KHV antibodies. The feasibility of DIVA strategies for KHVD was determined using these recombinant antigens to coat ELISA plates. Differential antibody responses were detected from carp sera to an internal virus tegument protein (rORF62) and external region of a transmembrane protein (rORF68). Fish vaccinated with an inactivated vaccine produced significantly lower antibody responses to rORF62 than to rORF68, whereas infected, exposed and live attenuated vaccinated fish recognised both proteins allowing differentiation between vaccinated and infected carp. However, the sensitivity of the assay was limited, possibly by high levels of natural antibodies detected at the relatively low serum dilutions (1/200) used. As the capsid antigen (ORF84) and tegument protein (ORF62) are derived from internal KHV structural proteins, they induce non-neutralising antibodies, which may be useful for DIVA strategies. Such antibodies are longer lasting than neutralising antibodies and often comprise the majority of fish anti-viral antibodies. This was noted in a fish surviving experimental challenge, which had an antibody titre of 1/10,000, but neutralising titre of 1/45. Such antigens may therefore hold potential for developing effective serological diagnostic tests for KHV and provide the potential for DIVA strategies against KHVD. Natural antibodies will, however, continue to present a challenge to the development of sensitive and reliable KHV serological tests, and hence the application of DIVA strategies.

Background: Horses are much predisposed and susceptible to excessive and acute inflammatory responses that cause the recruitment and stimulation of polymorphnuclear granulocytes (PMN) together with peripheral blood mononuclear cells (PBMC) and the release of cytokines. The aim of the study is to develop easy, quick, cheap and reproducible methods for measuring tumor necrosis factor alpha (TNF-α) and interleukin-1 receptor antagonist (IL-1Ra) in the equine whole blood cultures ex-vivo time- and concentration dependently. Results: Horse whole blood diluted to 10, 20 and 50 % was stimulated with lipopolysaccharide (LPS), PCPwL (a combination of phytohemagglutinin E, concanavalin A and pokeweed mitogen) or equine recombinant TNF-α (erTNF-α). TNF-α and IL-1Ra were analyzed in culture supernatants, which were collected at different time points using specific enzyme-linked immunosorbent assays (ELISA). Both cytokines could be detected optimal in stimulated 20 % whole blood cultures. TNF-α and IL-1Ra releases were time-dependent but the kinetic was different between them. PCPwL-induced TNF-α and IL-1Ra release was enhanced continuously over 24–48 h, respectively. Similarly, LPS-stimulated TNF-α was at maximum at time points between 8–12 h and started to decrease thereafter, whereas IL-1Ra peaked later between 12–24 h and rather continued to accumulate over 48 h. The equine recombinant TNF-α could induce also the IL-1Ra release. Conclusions: Our results demonstrate that similar to PCPwL, LPS stimulated TNF-α and IL-1Ra production time-dependently in whole blood cultures, suggesting the suitability of whole blood cultures to assess the release of a variety of cytokines in health and diseases of horse.